ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis.
Sara Charmsaz, Ben Doherty, Sinéad Cocchiglia...
https://pubmed.ncbi.nlm.nih.gov/33208158/Actively Recruiting
Led by Cancer Trials Ireland · Updated on 2025-12-19
1780
Participants Needed
6
Research Sites
421 weeks
Total Duration
Researchers are investigating the proteomic and molecular features of primary and recurrent or metastatic breast tumors. The study particularly focuses on the expression of S100 protein and the estrogen receptor ER, progesterone receptor PR, and HER2 genes. The aim is to deepen understanding of the molecular pathways that drive breast cancer progression and how these pathways respond to different treatments. The research also seeks to link proteomic results with survival data and to find potential blood markers that could indicate breast cancer progression. Participants will undergo standard treatment while tissue and blood samples are collected at various times. Tissue samples, both fresh frozen and formalin-fixed paraffin-embedded, will be taken during surgery or biopsy of primary or recurrentmetastatic tumors. Blood samples will be collected before neoadjuvant treatment if applicable, and before and after surgery or biopsy. For recurrent or metastatic cases without surgery, blood will be drawn before starting treatment. Additional blood samples will be taken annually for up to five years in primary cases and up to two years in recurrent or metastatic cases. Throughout the study, clinical data will be gathered alongside the biological samples to support the research. The primary outcome measure is the investigation of proteins and their pathways in primary breast cancer over ten years. Secondary outcomes include comparing molecular profiles between primary and recurrentmetastatic tumors, identifying new molecular mechanisms of recurrence, and finding potential targets for treatment. Participants will be followed and evaluated over the long term to support these research goals.
CONDITIONS
Breast Cancer Proteomics and Molecular Heterogeneity
C
Cancer Trials Ireland
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cancer Trials Ireland
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies based on treatment schedule
Participants undergo surgery or biopsy to collect tumor tissue samples and blood samples are taken before any neoadjuvant treatment or surgery.
1 visit for tissue collection and blood sampling (in-person)
Duration - Up to 5 years for primary cases; up to 2 years for recurrent/metastatic cases
Participants provide additional blood samples annually at follow-up visits for up to 5 years for primary cases and up to 2 years for recurrent/metastatic cases. Clinical data are collected at all times of biological sampling.
Annual visits for blood sampling and clinical data collection
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sara Charmsaz, Ben Doherty, Sinéad Cocchiglia...
https://pubmed.ncbi.nlm.nih.gov/33208158/Petra Jagust, Aoibhin M Powell, Mihaela Ola...
https://pubmed.ncbi.nlm.nih.gov/38852945/Sara Charmsaz, Éamon Hughes, Fiona T Bane...
https://pubmed.ncbi.nlm.nih.gov/28399921/Cancer Trials Ireland
Lead Sponsor